Interpace Diagnostics (Exotistan) Buy or Sell Recommendation

    Macroaxis provides Interpace Diagnostics Group Inc buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Interpace Diagnostics positions. The advice algorithm takes into account all of Interpace Diagnostics Group Inc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Interpace Diagnostics buy-and-hold prospective. Additionally take a look at Your Equity Center.

    Time Horizon

    Risk Tolerance

    Execute Advice
    Interpace Diagnostics Group Inc -- Exotistan Stock  

    USD 0.53  0.53  9,223,372,036,855%

    Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Interpace Diagnostics Group Inc is 'Not Rated'.
    For the selected time horizon Interpace Diagnostics Group Inc has a risk adjusted performance of 0.0, jensen alpha of 0.0, total risk alpha of 0.0, sortino ratio of 0.0 and treynor ratio of 0.0
    We provide buy, hold, or sell suggestion to complement the regular expert consensus on Interpace Diagnostics. Our dynamic recommendation engine utilizes multi - dimensional algorithm to analyze the organization potential to grow using all technical and fundamental data available at the time. To make sure Interpace Diagnostics Group Inc is not overpriced, please check out all Interpace Diagnostics fundamentals including its Net Income, Number of Employees, Z Score, as well as the relationship between Debt to Equity and Retained Earnings .
    Not Rated
    Alpha Finder
    Use alpha and beta coefficients to find investment opportunities after accounting for the risk
    Find Alpha
    Equity Screener
    Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals, sectors and families
    Research Equities
    Insiders Screener
    Find insiders across different sectors to evaluate their impact on performance and growth of their entities
    Research Insiders